透析患者肺炎球菌疫苗单独或联合流感疫苗的有效性与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项队列研究和1项准随机对照试验,共394,299例透析患者,评估肺炎球菌疫苗单独或联合流感疫苗接种的效果。结果显示,接种肺炎球菌疫苗与全因死亡和心血管事件风险降低相关,联合流感疫苗时全因死亡风险降低更明显,但证据确定性低,可能存在残余混杂或健康接种者偏倚。
要点
- 透析患者接种肺炎球菌疫苗与全因死亡风险降低相关(调整RR 0.73)。
- 肺炎球菌疫苗联合流感疫苗与全因死亡风险降低相关(调整RR 0.71)。
- 接种与未接种肺炎球菌疫苗的肺炎风险无差异,证据确定性低。
核心结论
- 使用肺炎球菌疫苗尤其联合流感疫苗与透析患者全因死亡风险降低相关,但可能受残余混杂或健康接种者偏倚影响。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Cochrane Library、Embase及三个中文数据库至2020年2月29日,纳入干预性、队列和病例对照研究。
- 最终纳入5项队列研究和1项准随机对照试验,共394,299例透析患者,证据质量中至高级。
主要发现
- 与未接种者相比,接种肺炎球菌疫苗者全因死亡风险降低(调整RR 0.73,95%CI 0.67-0.79,I2=31.1%,GRADE低确定性)。
- 与未接种者相比,接种肺炎球菌疫苗者心血管事件风险降低(调整RR 0.80,95%CI 0.69-0.93,I2=47.2%,GRADE低确定性),未报告严重不良反应。
- 与未接种者相比,肺炎球菌疫苗联合流感疫苗者全因死亡风险降低(调整RR 0.71,95%CI 0.67-0.75,I2=63.3%)。
- 与未接种者相比,单独接种肺炎球菌疫苗者全因死亡风险降低(调整RR 0.86,95%CI 0.78-0.94,I2=0%),单独接种流感疫苗者全因死亡风险降低(调整RR 0.76,95%CI 0.73-0.79,I2=0%)。
- 接种与未接种肺炎球菌疫苗的患者肺炎风险无差异;既往接种多糖肺炎球菌疫苗-23者对肺炎球菌结合疫苗-13的免疫应答弱于未接种者。
关键数值与推荐
- 全因死亡:接种肺炎球菌疫苗 vs 未接种,调整RR 0.73(95%CI 0.67-0.79),GRADE低确定性。
- 心血管事件:接种肺炎球菌疫苗 vs 未接种,调整RR 0.80(95%CI 0.69-0.93),GRADE低确定性。
- 全因死亡:肺炎球菌疫苗联合流感疫苗 vs 未接种,调整RR 0.71(95%CI 0.67-0.75)。
- 全因死亡:单独肺炎球菌疫苗 vs 未接种,调整RR 0.86(95%CI 0.78-0.94);单独流感疫苗 vs 未接种,调整RR 0.76(95%CI 0.73-0.79)。
临床怎么用
- 透析患者可考虑接种肺炎球菌疫苗,尤其是联合流感疫苗接种,以降低全因死亡风险。
- 既往接种多糖肺炎球菌疫苗-23者接种肺炎球菌结合疫苗-13的免疫应答可能较弱,需关注接种策略。
局限性
- 纳入研究以队列为主,可能存在残余混杂和健康接种者偏倚。
- 全因死亡和心血管事件证据的GRADE确定性为低。
- 肺炎结局未显示差异,相关证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A lower conversion vaccination rate and a more rapid decline in antibody titers over time in dialysis patients raise concerns about the effectiveness of pneumococcal vaccination (PV) in this population, which has not been systematically reviewed. METHODS: We searched PubMed, Cochrane Library, Embase and three Chinese databases from inception until February 29th, 2020 for interventional, cohort and case-control studies evaluating PV alone or combined with influenza vaccination (IV) on outcomes (all-cause mortality, pneumonia, cardiovascular events, antibody response and safety). Independent reviewers completed citation screening, data extraction, risk assessment, meta-analysis, and GRADE rating of the quality of evidence. RESULTS: Five cohort studies and one quasirandomized control trial enrolling 394,299 dialysis patients with high to moderate quality were included. Compared with unvaccinated individuals, those receiving PV had lower risk of all-cause mortality [Adjusted relative risk (RR) 0.73, 95% CI 0.67-0.79, I2 = 31.1%, GRADE low certainty] and cardiovascular events (adjusted RR 0.80, 95% CI 0.69-0.93, I2 = 47.2%, GRADE low certainty) without serious adverse effect reported. Compared with no vaccination, lower all-cause mortality was observed in those receiving PV combined with IV (Adjusted RR 0.71, 95%CI 0.67-0.75, I2 = 63.3%), PV alone (Adjusted RR 0.86, 95% CI 0.78-0.94,I2 = 0%], and IV alone (Adjusted RR 0.76, 95% CI 0.73-0.79, I2 = 0%]. There was no difference between pneumococcal vaccinated patients vs non-vaccinated patients with respect to pneumonia. Immune response to pneumococcal conjugate vaccine-13 was weaker in polysaccharide pneumococcal vaccine-23-pre-vaccinated compared with vaccine-naive patients. CONCLUSIONS: The use of pneumococcal vaccine especially combined with influenza vaccination is associated with lower risks of all-cause mortality but may be affected by residual confounding/healthy vaccinee bias.
引用
- Mo Y, Zeng J, Xiao C, et al. Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: A systematic review and meta-analysis. Vaccine. 2020. PMID: 33059969. doi:10.1016/j.vaccine.2020.09.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。